Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
LUX-VALVE PLUS TRAVEL II
RESULTS RELEASED AT THE 2023 TCT IN THE U.S.

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board ("**Board**") of directors ("**Directors**") of the Company is pleased to announce that recently, the results of multicenter clinical trial of LuX-Valve Plus transvascular tricuspid valve replacement system ("**TRAVEL II**") were officially published at the 2023 Transcatheter Cardiovascular Therapeutics Conference ("**TCT**") by Academician Ge Junbo from Zhongshan Hospital affiliated to Fudan University (復旦大學附屬中山醫院).

TRAVEL II is a prospective, multicenter and single-arm clinical trial, which primarily evaluates the long-term safety and efficacy of LuX-Valve Plus in the application on patients with severe tricuspid regurgitation. The TRAVEL II clinical trial enrolled 96 patients from 15 centers in China. The primary endpoint of the one-month clinical data released was the composite event rate within 30-days after the procedures.

The results of this clinical research showed:

(1) Both the device success rate and procedure success rate were 96.84%; and

(2) The average device operation time was 35.56±20.82 minutes.

The 30-day efficacy results showed:

(1) Tricuspid regurgitation was reduced to mild or less in all patients, and 97.81% of patients showed no or only trivial paravalvular leak; and

(2) In terms of New York Heart Association ("**NYHA**") cardiac function improvement and quality of life scores, 80.43% of patients improved from pre-procedure NYHA class III/IV to class I/II, 34.78% of patients improved their Kansas City Cardiomyopathy Questionnaire ("**KCCQ**") scores by greater than or equal to 20 points, and 26.09% of patients improved their KCCQ scores by 10 to 19 points.

The 30-day safety results showed:

Clinical Event Committee (CEC)-adjudicated Composite Events at 30 Days (N=93)

All-cause death	1 (1.1%)
New onset III°AVB requiring permanent pacemaker implantation	2 (2.2%)
Severe paravalvular leakage	1 (1.1%)
Acute renal failure	1 (1.1%)
Conversion to surgical tricuspid valve replacement or tricuspid valvuloplasty	1 (1.1%)
Stroke	0 (0.0%)
Myocardial infarction	0 (0.0%)
Requirement of ECMO or IABP	0 (0.0%)
Long-term mechanical ventilation (>72 hours)	0 (0.0%)
Acute liver failure	0 (0.0%)
Cardiovascular injury requiring surgical intervention (heart perforation, vascular injury)	0 (0.0%)
Life-threatening massive bleeding	0 (0.0%)
Composite event rate	**6 (6.45%)**

The TRAVEL II study showed LuX-Valve Plus features short device time, a lower 30-day composite event rate, an improvement of cardiac function and life quality.

As of the date of this announcement, nearly 500 implantation cases have been completed worldwide for transcatheter tricuspid valve replacement system products independently developed by the Company, and the longest follow-up record was over 5 years. The Company will continue to promote the commercialization of its products in China, Europe, the U.S. and the Asia-Pacific region.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, October 31, 2023

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.